Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

LianBio Sells Rights for RSV Therapy to Pfizer in $155 Million Deal

publication date: Dec 20, 2022

LianBio, a Princeton-Shanghai in-licensing company, announced that Pfizer will exercise an option to develop and commercialize a novel respiratory syncytial virus (RSV) therapy candidate in Greater China. Sisunatovir is an oral fusion inhibitor designed to block RSV replication. LianBio will receive $20 million upfront and up to $135 million in milestones plus royalties. Two years ago, LianBio and Pfizer formed a collaboration to develop novel products for China, with ReViral’s sisunatovir the first candidate. LianBio acquired China rights to the candidate from ReViral in early 2021. More details....

Stock Symbols: (NSDQ: LIAN) (NYSE: PFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital